Endokrino­logie
und
Diabetologie

01.08.2003 bis 31.08.2021 Universitätsprofessor für Innere Medizin mit den Schwerpunkten Endokrinologie und Stoffwechsel der Ruhr Universität Bochum und Direktor der Med. Klinik 1, Berufsgenossenschaftliche Universitätskliniken Bergmannsheil

​2017-2022 „TOP-Mediziner“ im Bereich Diabetologie in der Focus Ärzteliste

2007-2021 Vorsitzender der Nordrhein-Westfälischen Gesellschaft für Endokrinologie und Diabetologie

2015 – jetzt Mitglied der Kommission Leitlinien der Deutschen Gesellschaft für Innere Medizin

2015-2021 Autorenschaft bei der „Nationalen Versorgungsleitlinie Typ 2 -Diabetes“ (AWMF nvl-001, 2021) sowie den S3- Leitlinien „Therapie des Typ 1-Diabetes“ (2018) und  „Ernährungsempfehlungen zur Behandlung des Diabetes mellitus –Proteinzufuhr“ (2015)

2015-2022 Chair, Committee on Clinical Affairs (CCA) der European Association for the Study of Diabetes (EASD)

2011-2021 Mitglied des Kuratoriums des Deutschen Diabeteszentrums (DDZ) in Düsseldorf

2011-2013 Vorstandsmitglied und Kongresspräsident 2013 der Deutschen Diabetes Gesellschaft

2007-2012 CHMP Endocrinology/Diabetes der European Medicines Agency

2003-2009 Vorstandsmitglied und Pressesprecher der Deutschen Gesellschaft für Endokrinologie

​​2002 – 2003  leitender Oberarzt und Bereichsleitung Endokrinologie und Diabetologie, Med. Klinik IV, Universitätsklinikum Tübingen

1996 – 2002 Bereichsleitung „Endokrinologie/Diabetologie“ der Medizinischen Klinik I, Universtätsklinikum Lübeck

1986-1996 Assistenz- und ab 1994 Oberarzt der Medizinischen Klinik I, Universitätsklinikum Lübeck

1994 Arzt für Innere Medizin – Endokrinologie und Diabetologie

1991 Arzt für Innere Medizin

​1983-1986 „Postdoctoral Fellow“, Division of Endocrinology and Metabolism, University of California, San Diego

1. Klein, H (1982) Untersuchungen an isolierten Langerhansschen Inseln zur Rolle der mitochondrialen Atmung bei der Auslösung der Insulinsekretion. Dissertation, Universtät Göttingen (1982)
2. Panten U, Klein H (1982) O2-consumption by isolated pancreatic islets as measured in a microincubation system with a Clark-type electrode. Endocrinology 111: 1595-1600
3. Klein HH, Freidenberg GR, Cordera R, Olefsky JM (1985) Substrate specificities of insulin and epidermal growth factor receptorkinases. Biochem Biophys Res Comm 127: 254-263
4. Freidenberg GR, Klein HH, Cordera R, Olefsky JM (1985) Insulin receptor kinase in rat liver: Regulation by fasting and high carbohydrate feeding. J Biol Chem 260: 12444-12453
5. Freidenberg GR, Klein HH, Kladde MP, Cordera R, Olefsky JM (1986) Regulation of epidermal growth factor receptor number and phosphorylation by fasting in rat liver. J Biol Chem 261: 752-757
6. Klein HH, Freidenberg GR, Kladde MP, Olefsky JM (1986) Insulin activation of insulin receptor kinase in intact rat adipocytes: An in vitro system to measure histonekinase activity of insulin receptors activated in vivo. J Biol Chem. 261: 4691-4697
7. Freidenberg GR, Henry RR, Klein HH, Reichart DR, Olefsky JM (1987) Decreased kinase activity of insulin receptors from adipocytes of non-insulin dependent diabetic (NIDDM) subjects. J Clin Invest 79: 240-250
8. Klein HH, Ciaraldi TP, Freidenberg GR, Olefsky JM (1987) Adenosine modulates insulin activation of insulin receptor kinase in intactrat adipocytes. Endocrinology 120: 2339-2345
9. Klein HH, Freidenberg GR, Matthaei S, Olefsky JM (1987) Insulin receptor kinase following internalization in isolated rat adipocytes. J Biol Chem 262 10557-10564
10. Brillon DJ, Henry RR, Klein HH, Olefsky JM, Freidenberg G (1988) Functional and structural differences in human and rat-derived insulin receptors: Characterization of the ß-subunit kinase activity. Endocrinology 123: 1837-184
11. Matthaei S, Benecke H, Klein HH, Hamann G, Kreymann G, Greten H (1990) Potential mechanism of insulin resistance in ageing: impaired insulin-stimulated glucose transport due to a depletion of the intracellular pool of glucose transporters in Fischer rat adipocytes. J Endocrinology 126: 99-107
12. Matthaei S, Hamann A, Klein HH, Benecke H, Kreymann G, Flier S, Greten H (1991) Association of metformin´s effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from an intracellular pool to the plasma membrane in rat adipocytes. Diabetes 40: 850-857
13. Klein HH, Matthaei S, Drenckhan M, Ries W, Scriba PC (1991) The relationship between insulin binding, insulin-activation of insulin receptortyrosine kinase, and insulin-stimulation of glucose uptake in isolated rat adipocytes. Biochem J 274:
    787-792
14. Matthaei S, Hamann A, Klein HH, Benecke H, Kreymann G, Flier S, Greten H (1992) Evidence that metformin increases insulin-stimulated glucose uptake by potentiating insulin-induced translocation of glucose transporters from an intracellular pool to the cell surface in rat adipocytes. Horm Metab Res 26 ( Suppl): 34-41
15. Benecke H, Flier J, Rosenthal N, Siddle K, Klein HH, Moller DE (1993) Muscle-specific expression of the human insulin receptor in transgenic mice. Diabetes 42 206-212
16. Klein HH, Kowalewski B, Drenckhan M, Neugebauer S, Matthaei S, Kotzke G (1993) A microtiter well assay system to measure insulin-activation of insulin receptor kinase in intact human mononuclear cells: decreased insulin effect in cells
    from patients with NIDDM. Diabetes 42: 883-890
17. Klein HH, Kowalewski B (1993) A microtiter well assay system to measure the activity state of insulin receptor kinase resulting from stimulation of intact human adipocytes with insulin: Comparison of the activity state „in vivo“ and following subsequent maximal deactivation and/or activation of the same receptors „invitro“. Exp Clin Endocrinol Diabetes 101: 336-337
18. Quentmeier A, Daneschmand H, Klein HH, Probst I (1993) Insulin-mimetic actions of phorbol-ester in cultured adult rat hepatocytes. Lack of phorbol ester-elicited inhibition of the insulin signal. Biochem J 289: 549-555
19. Quentmaier A, Klein HH, Unthan-Fechner K, Probst I (1993) Attenuation of insulin actions in primary rat hepatocyte cultures through complexation of vicinalthiols by phenylarsine oxide. Biol Chem Hoppe-Seyler 374: 965-971
20. Matthaei S, Reibold J-P, Hamann A, Häring HU, Greten H, Klein HH (1993) In vivo metformin-treatment ameliorates insulin resistance. Evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology 133: 304-31
21. Klein HH, Vestergaard H, Kotzke G, Pedersen O (1995) Elevation of serum insulin concentration during euglycemic hyperinsulinemic clamp studies leads to similar activation of insulin receptor kinase in muscle of subjects with and without NIDDM. Diabetes 44: 1310-1317
22. Kotzke G, Schütt M, Missler U, Moller DE, Fehm HL, Klein HH (1995) Binding of human, porcine and bovine insulin to insulin receptors from human brain, muscle and adipocytes, and to expressed recombinant alternatively spliced receptor
    isoforms. Diabetologia 38: 757-763
23. Matthaei S, Trost B, Hamann A, Kausch C, Benecke H, Greten H, Höppner W, Klein HH (1995) Effect of in vivo thyroid hormone status on insulin signalling and GLUT1 and GLUT4 glucose transport systems in rat adipocytes. J Endocrinol 144:
    347-357
24. Vestergaard H, Klein HH, Hansen T, Müller J, Skovby F, Bjorbak C, Roder M, Pedersen O (1995) Severe insulin resistant diabetes in patients with congenital muscle fibre type disproportion myopathy. J Clin Invest 95: 1925-1932
25. Hansen BF, Danielsen G, Dreijer K, Sorensen A, Wiber F, Klein HH, Lundemose AG (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues with increased mitogenic potency. Biochem J 315: 271-279
26. Klein HH, Kowalewski B, Drenckhan M, Fehm HL (1996) Insulin stimulation of human adipocytes activates the kinase of only a fraction of the insulin receptors. Am J Physiol 272: E576-E583
27. Baba T, Drenckhan M, Neugebauer S, Klein H Effect of angiotensin II and bradykinin on insulin-stimulated tyrosine kinase activity of the insulin receptor. Diabetologia 41 (1998) 742-743
28. Gebken J, Luders B, Notbohm H, Klein HH, Brinckmann J, Muller PK, Bätge B (1999) Hypergravity stimulates collagen synthesis in human osteoblast-like cells: evidence for the involvement of p44/42 MAP-kinases (ERK 1/2). J Biochem 126:
    676-682
29. Klein HH, Müller R, Vestergaard H, Pedersen O (1999) Implications of compound heterozygous insulin receptor mutations in congenital muscle fibre type disproportion myopathy for the receptor kinase activation. Diabetologia 42: 245-249
30. Krützfeldt J, Grünweller A, Raasch W, Drenckhan M, Klein HH (1999) Microtiter well assays for protein tyrosine phosphatase activities directed against phosphorylated insulin receptor or insulin receptor substrate-1. Anal Biochem 271: 97-99
31. Bätge B, Feydt A, Gebken J, Klein H, Notbohm H, Müller PK, Brinckmann J (2000) Age-related differences in the expression of receptors for TGF-ß in human osteoblast-like cells in vitro. Exp Clin Endocrinol Diabet 108: 311-315
32. Bossenmaier B, Strack V, Stoyanov B, Krützfeldt J, Beck, A, Lehmann R, Kellerer M, Klein HH, Ullrich A, Lammers R, Häring HU (2000) Serine residues 1177/78/82 of the insulin receptor are required for substrate but not autophosphorylation. Diabetes 49 : 889-895
33. Klein HH, Müller R, Drenckhan M, Schütt M, Bätge B, Fehm HL (2000) Insulin activation of insulin receptor kinase in erythrocytes is not altered in non-insulin-dependent diabetes and not influenced by hyperglycemia. J Endocrinol 166: 275-281
34. Krützfeldt J, Kausch C, Volk A, Klein HH, Rett K, Häring HU, Stumvoll M (2000) Insulin signaling and action in cultured skeletal muscle cells from lean, healthy humans with high and low insulin sensitivity. Diabetes 49 992-998
35. Krützfeldt J, Raasch W, Klein HH (2000) Ramipril increases the protein level of skeletal muscle insulin receptor substrate-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats. N-S Arch Pharmacol 362: 1-6.
36. Ludwig M, Klein HH, Diedrich K, Ortmann O (2000) Serum leptin concentrations throughout the menstrual cycle. Arch Gynecol Obstet 263: 99-101
37. Strack V, Hennige AM, Krützfeldt J, Bossenmaier B, Klein HH, Kellerer M, Lammers R, Häring HU (2000) Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition byprotein kinase C isoforms 2 and .
    Diabetologia 43: 443-449
38. Schütt M, Drenckhan M, Benecke H, Klein HH (2000) Functional characteristics of Ser1200-mutated insulin receptors. Eur J Endocrinol 143: 125-131
39. Schütt M, Meier M, Drenckhan M, Meyer S, Aries SP, Klein HH (2000) The HIV-protease inhibitor indinavir impairs insulin signaling in HepG2 cells. Diabetologia 43: 1145-1148
40. Grimmsmann T, Levin K, Meyer M, Beck-Nielsen H, Klein HH (2002) Delays in insulin signaling towards glucose disposal in human skeletal muscle. J Endocrinol 172:645-651
41. Jost P, Fasshauer M, Kahn CR, Benito M, Meyer M, Ott V, Lowell BB, Klein HH, Klein J (2002) Atypical ß-adrenergic effects on insulin signaling and action in ß3-adrenoreceptor-deficient brown adipocytes. Am J Physiol Endocrinol Metab 283: E146-53
42. Klein J, Fasshauer M, Klein HH, Benito M, Kahn, CR (2002) Novel adipocyte lines from brown fat: A model system for the study of differentiation, energy metabolism, and insulin action. Bioessays 24: 382-388
43. Kraus D, Fasshauer M, Ott V, Jost M, Kahn CR, Klein HH, Klein J (2002) Leptin secretion and negative autocrine crosstalk with insulin in brown adipocytes. J Endocrinol 175:185-91.
44. Klein HH, Ullmann S, Drenckhan M, Unthan-Fechner K, Probst I (2002) Influence of dexamethasone on insulin actions: Studies in primary cultures of rat hepatocytes. J Hepatology 37 432-440
45. Meyer MM, Levin K, Grimmsmann T, Beck-Nielsen H, Klein HH (2002) Insulin signaling in skeletal muscle of subjects with or without type 2-diabetes and first degree relatives of patients with the disease. Diabetologia 45: 813-822
46. Meyer MM, Levin K, Grimmsmann T, Perwitz N, Eirich A, Beck-Nielsen H, Klein HH (2002) Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of diabetes. Diabetes 51: 2691-2697
47. Ott V, Fasshauer M, Dalski A, Klein HH, Klein J (2002) Direct effects of ciliary neurotrophic factor on brown adipocytes: Evidence for a role in peripheral regulation of energy homeostasis. J Endocrinol 173: R1-8
48. Ott V, Fasshauer M, Dalski A, Meier B, Klein HH, Tschöp M, Klein J (2002) Direct peripheral effects of ghrelin include suppression of adiponectin expression. Horm Metab Res 34:640-5
49. Schütt M, Meier MM, Jost MM, Klein HH (2003) The HIV protease inhibitor indinavir impairs glycogen synthesis in HepG2-hepatoma cells but does not affect phosphotyrosine phosphatase activity against phosphorylated insulin receptor substrate 1. Exp Clin Endocrinol Diabetes 111:16-20
50. Wolfrum S, Dendorfer A, Schütt M, Weidtmann B, Tempel K, Klein HH, Dominiak P, Richardt G (2004) Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide (PI) 3-Kinase/Akt pathway. J Cardio-vasc Pharm 44:348-355
51. Klein J, Westphal S, Kraus D, Meier B, Perwitz N, Ott V, Fasshauer M, Klein HH (2004) Metformin inhibits leptin secretion via a mitogen-activated protein (MAP) kinase signaling pathway in adipocytes. J Endocrinol 183:299-307
52. Schütt M, Zhou J, Meier M, Klein HH (2004) Long-term effects of HIV-protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. J Endocrinol 183: 445-45
53. Bosy-Westphal A, Brabant G, Haas V, Onur S, Paul T, Nutzinger D, Klein H, Hauer M, Muller MJ (2005) Determinants of plasma adiponectin levels in patients with anorexia nervosa examined before and after weight gain. Eur J Nutr 355-959
54. Haas V, Onur S, Paul T, Nutzinger DO, Bosy-Westphal A, Hauer M, Brabant G, Klein H, Müller MJ (2005) Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery Am J Clin Nutr 81:889-896
55. Jost MM, Jost P, Klein J, Klein HH (2005) ß3-adrenergic agonist CL316, 243 inhibits insulin signaling but not glucose uptake in primary human adipocytes. Exp Clin Endocrinol Diabetes 113:418-422
56. Onur S, Haas V, Bosy-Westphal A, Hauer M, Paul T, Nutzinger D, Klein H, Müller MJ (2005) L-Tri-iodothyronine is a major determinant of resting energy expenditure in underweight patients with anorexia nervosa and during weight gain. Eur J Endocrinol 152:179-84.
57. Schneider S, Feilen PJ, Schreckenberger M, Schwanstecher M, Schwanstecher C, Buchholz HG, Thews O, Oberholzer K, Korobeynikov A, Bauman A, Comagic S, Piel M, Schirrmacher E, Shiue CY, Alavi AA, Bartenstein P, Rosch F, Weber MM,
    Klein HH, Schirrmacher R (2005) In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans. Exp Clin Endocrinol Diabetes 113:388-95
58. Schneider S, Klein HH (2005) Inosine improves islet xenograft survival in immuno- competent diabetic mice. Eur J Med Res 10:283-286
59. Meyer MF, Czaplewski H, Braun J, Hellmich B, Schatz H, Klein HH (2005) Lack of a difference in increased capillary blood cell velocity in the skin over proximal inter-phalangeal joints between rheumatoid arthritis and osteoarthritis.
    Microvasc Res 70:1-6
60. Meier M, Klein HH, Kramer J, Drenckhan M, Schutt M (2007) Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling. J Endocrinol 193:45-51
61. Meyer MF, Schmidt O, Hellmich B, Schatz H, Klein HH, Braun J (2007) Micro-vascular dysfunction in rheumatoid arthritis assessed by laser Doppler anemometry: relationship to soluble adhesion molecules and extraarticular manifestations. Rheumatol Int 28:145-52
62. Schneider S, Ueberberg S, Korobeynikov A, Schechinger W, Schwanstecher C, Schwanstecher M, Klein HH, Schirrmacher E. (2007) Synthesis and evaluation of a glibenclamide glucose-conjugate: A potential new lead compound for substituted glibenclamide derivatives as islet imaging agents. Regul Pept 139 122-127
63. Sudhaus S, Fricke B, Schneider S, Stachon A, Klein H, von During M, Hasenbring M (2007) The cortisol awakening response in patients with acute and chronic low back pain: Relations with psychological risk factors of pain chronicity. Schmerz 21:202-211
64. Orcy RB, Schroeder S, Martins-Costa SH, Ramos JG, Schechinger W, Klein H, Brum IS, von Eye Corleta H, Capp E (2008) Signalization of Akt/PKB in the placenta, skeletal muscle and adipose tissue of preeclampsia patients. Gynecol Obstet Invest 66(4):231-6
65. Meyer MF, Lieps D, Schatz H, Klein HH, Pfohl M (2008) Influence of the duration of type 2 diabetes on early functional and morphological markers of atherosclerosis compared to the impact of classic cardiovascular risk factors. Exp Clin Endocrinol Diabetes 116:298-304
66. Dietrich JW, Stachon A, Antic B, Klein HH, Hering S (2008) The AQUA-FONTIS Study: Protocol of a multidisciplinary, cross-sectional and prospective longitudinal study for developing standardized diagnostics and classification of non-thyroidal illness syndrome. BMC Endocr Disord 8:13-22
67. Viebahn R, Klein H, Kraemer B, Schenker P (2009) Is Pancreas Transplantation Getting Old? Single-center Experience in an Aging Society. Clinical Transplants Chapter 12
68. Sudhaus S, Fricke B, Stachon A, Schneider S, Klein H, Düring M, Hasenbring M (2009) Salivary cortisol and psychological mechanisms in patients with acute versus chronic low back pain. Psychoneuroendocrinology 34, 513—522
69. Meyer M, Rose CJ, Schatz H, Klein HH (2009) effects of a short term improvement in glycemic control on skin microvascular dysfunction in type 1 and type 2 diabetic subjects. Diabetic Medicine 26 880-886
70. Ueberberg S, Meier JJ, Waengler C, Schechinger W, Dietrich JW, Tannapfel A, Schmitz I, Schirrmacher R, Köller M, Klein HH, Schneider S (2009) Generation of novel single-chain antibodies by phage-display technology to direct imaging agents
    highly selective to pancreatic {beta}- or {alpha}-cells in vivo. Diabetes 58:2324-34.
71. Mues C, Zhou J, Manolopoulos KN, Korsten P, Schmoll D, Klotz LO, Bornstein SR, Klein HH, Barthel A (2009) Regulation of Glucose-6-Phosphatase Gene Expression by Insulin and Metformin. Horm Metab Res 41:730-5
72. Meier JJ, Köhler CU, Alkhatib B, Sergi C, Junker T, Klein HH, Schmidt WE, Fritsch H (2010) β-cell development and turnover during prenatal life in humans. Eur J Endocrinol 2010 162: 559-568
73. Viebahn R, Klein H, Kraemer B, Schenker P (2009) Is pancreas transplantation getting old? Single-center experience in an aging society. Clin Transpl. 2009:165-699.
74. Ueberberg S, Ziegler D, Schechinger W, Dietrich JW, Akinturk S, Klein HH, Schneider S (2010) In vitro phage display in a rat beta cell line: a simple approach for the generation of a single-chain antibody targeting a novel beta cell-specific
    epitope. Diabetologia 53:1384-1394.
75. Hartleb S, Plöckinger U, Stalla GK, Tuschy U, Weber MM, Pfützner A, Kann PH; German KIMS Board; German KIMS Pharmacogenetics Study Group (2011) Additive effect of GHRd3 and COLIA1 polymorphisms on the GH-substitution dose in GH-deficient adults. Pharmacogenomics12:1653-1661
76. Schneider S, Klein HH (2011) Preserved insulin secretion capacity and graft function of cryostored encapsulated rat islets. Regul Pept 166:135-138
77. Schneider S, Klein HH (2011) Long-term graft function of cryostored alginate encapsulated rat islets. Eur J Med Res 16:396-400.
78. Ueberberg S, Deutschbein T, Klein HH, Dietrich JW, Akinturk S, Prochnow N, Schirrmacher R, Schneider S (2011) Protection from diabetes development by single-chain antibody-mediated delivery of a NF-kappa B inhibitor specifically to beta-cells in vivo. Am J Physiol Endocrinol Metab 301:E83-90
79. Giebelstein J, Poschmann G, Højlund K, Schechinger W, Dietrich JW, Levin K, Beck-Nielsen H, Podwojski K,  Stühler K, Meyer HE, Klein HH (2012) The proteomic signature of insulin resistant human skeletal muscle reveals increased glycolytic and decreased mitochondrial enzymes. Diabetologia 55:1114-1127
80. Schöfl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B, Schopohl J, participants of the German Acromegaly Register. (2013) Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol 168:39-47
81. Goede SL, Leow MK, Smit JW, Klein HH, Dietrich JW (2014) Hypothalamus-Pituitary-Thyroid Feedback Control: Implications of Mathematical Modeling and Consequences for Thyrotropin (TSH) and Free Thyroxine (FT4)
    Reference Ranges. Bull Math Biol 76:1270-87
82. Dietrich JW, Müller P, Schiedat F, Schlömicher M, Strauch J, Chatzitomaris A, Klein HH, Mügge A, Köhrle J, Rijntjes E, Lehmphul I (2015) Nonthyroidal Illness Syndrome in Cardiac Illness Involves Elevated Concentrations of 3,5-Diiodothyronine and Correlates with Atrial Remodeling. Eur Thyroid J DOI: 10.1159/000381543
83. Chatzitomaris A, Hoermann R, Midgley JE, Hering S, Urban A, Dietrich B, Abood A, Klein HH, Dietrich JW (2017) Thyroid Allostasis-Adaptive Responses of Thyrotropic Feedback Control to Conditions of Strain, Stress, and Developmental Programming. Front Endocrinol (Lausanne). 8:163. doi:10.3389/fendo.2017.00163. eCollection 2017
84. Maasberg S, Pape UF, Fottner C, Goretzki PE, Anlauf M, Hörsch D, Cremer B, Schulte DM, Quietzsch D, Scheerer F, Pöpperl G, Poeppel TD, Begum N, Grohé C, Rinke A, Plöckinger U, Wiedenmann B, Arnold R, Neuhaus P, Knapp WH, Lehnert H, Auernhammer C, Pavel M, von Weikersthal LF, Schmidt B, Klein HH, Essler M, Neumann JD, Hamann S, Steffens F, Demtröder F, Kröcher A, Zoicas F, Lahner H, Weber F, Geißler M, Raffel A, Krausch M, Zimmermann P, Lerch MM, Wirth T, Lang M, Ezziddin S, Lammert F, Bischoff M, Altendorf-Hofmann A, Müller L, Hoffmeister A, Klose S, Musholt TJ, Post S, Gertler R, Scheuerlein H, Bergmann T, Bisping G, Knauerhase A, Rendenbach B, Groß V, Scheurlen M,
    Mönig H, Kudlich T, Grabowski P, Musholt TJ, Watza F, Scheidhauer K, Möbius E (2018) Neuroendocrine Neoplasia within the German NET Registry. Z Gastroenterol 56:1237-1246
85. Röhling M, Martin T, Wonnemann M, Kragl M, Klein HH, Heinemann L, Martin S, Kempf K (2019) Determination of postprandial glycemic responses by continuous glucose monitoring in a real-world setting. Nutrients 11, doi:10.3390/nu11102305
86. Müller P, Dietrich JW, Lin T, Bejinariu A, Binnebößel S, Bergen F, Schmidt J, Müller SK, Chatzitomaris A, Kurt M, Gerguri S, Clasen L, Klein HH, Kelm M, Makimoto H (2020) Usefulness of Serum Free Thyroxine Concentration to Predict Ventricular Arrhythmia Risk in Euthyroid Patients With Structural Heart Disease. Am J Cardiol. 125:1162-1169

Fallberichte

1. Rohe M, Unger H, Henrichs HR, Kerner W, Schier H, Klein HH (1997) Insulinbedarf von mehr als 3000I.E./Tag bei einer 29jährigen Patientin mit Diabetes. Diabetes und Stoffwechsel 6: 28-33
2. Schütt M, Aries SP, Rosenfeldt M, Peters A, Klein HH (2000) Short term treatment with indinavir fails to reduce the glucose requirement in a patient with malignant insulinoma Am J Med 108: 524
3. Bätge B, Struck J, Klein HH, Brinckmann J (2000) Schwere Vitamin D-Mangel-Osteomalazie durch Koinzidenz mehrerer Risikofaktoren. Deut Med Wschr 125: 761-765
4. Schütt M, Lorch H, Krüger S, Peters A, Klein HH (2001) Rezidivierende Hypoglykämien bei malignem Insulinom: Chemoembolisation als Therapieoption. Med Klin 96: 632-636
5. Klein J, Ott V, Schütt M, Klein HH (2002) Recurrent hypoglycemic episodes in a patient with type 2-diabetes under fibrate therapy. J Diabetes Complications 16: 246-248
6. von Sengbusch A, Tannapfel A, Klein HH, Hering S (2010) Hepatomegalie und erhöhte Transaminasen bei einer 24-jährigen Patientin mit Typ 1-Diabetes mellitus. Internist 51:84-87
7. Manolopoulos KN, Barthel A, Nicolas V, Klein HH, Hering S (2010) Necrotizing fasciitis of the back musculature as a complication of acquired perforating collagenosis in diabetes mellitus. J Clin Endocrinol Metab 95:11-12
8. Dietrich JW, Ehren M, Ruff-Dietrich S, Klein HH (2013) 43-year-old woman with diabetes and postoperative circulatory collapse. Dtsch Med Wochenschr 138:945
9. Chatzitomaris A, Scheeler M, Gotzmann M, Köditz R, Schildroth J, Knyhala KM, Nicolas V, Heyer C, Mügge A, Klein HH, Dietrich JW (2015) Second degree AV block and severely impaired contractility in cardiac myxedema: a case report. Thyroid Res. 8:6.
10. Chatzitomaris A, Eisenhofer G, Williams TA, Worms O, Nicolas V, Reincke M , Klein HH Steroid profiling as an additional tool to confirm one-sided hormone overproduction in primary aldosteronism: a case report. Frontiers Endocrin doi: 10.3389/fendo.2019.00597. eCollection 2019.PMID: 31555214

Übersichtsarbeiten

1. Klein HH (1989) Insulinrezeptoren und Insulinresistenz. FOCUS MHL 1: 6-8
2. Klein HH, Häring HU (1990) Pathogenese des Diabetes mellitus Typ II. Internist 31: 168-179
3. Klein, HH (1992) Ätiologie und Pathogenese des Typ-II-Diabetes. Med Welt 43 216-221
4. Beguinot F, Häring H, Kiess W, Klein H, Sesti G, Smith U, Van Obberghen E (1998) The search for NIDDM genes project: A european community programme aimed to facilitate the identification of NIDDM genes. Diabetologia 41 (1) 15-16
5. Kern W, Stange EF, Fehm HL, Klein HH (1999) Glukokortikoid-induzierter Diabetes mellitus bei gastroenterologischen Erkrankungen. Z Gastroenterol 13, Suppl 1: 36-42
6. Schütt M, Meier M, Klein HH (2003) Das HIV-Proteasehemmer-induzierte Insulinresistenzsyndrom. Med Klin 98 271-276
7. Ehren M, Klein HH (2004) Hypoglykämien bei der Behandlung von Diabetes: Patienten und Bezugspersonen für den Ernstfall trainieren. CardioVasc
8. Klein HH (2004) Aktuelle Kontroversen in der Endokrinologie. MMW-Fortschr. Med. 9 121
9. Roggenland D, Schneider S, Klein HH, Kann PH (2006) Endosonographie – eine zusätzliche Möglichkeit bei der Differenzierung der häufigsten Formen des Hyperaldosteronismus. Med Klin 101 65-68
10. Schneider S, Padzierny G, Klein HH (2006) Orale antidiabetische Therapie. Deut Med Wschr 131:S264-S268
11. Meier JJ, Schmidt WE, Klein HH (2007) Neue Konzepte in der Behandlung des Typ 2-Diabetes. Internist 48 798-707
12. Meyer MF, Daigeler A, Lehnhardt M, Steinau HU, Klein HH (2007) Therapeutic management of acral manifestations of systemic sclerosis. Med Klin 102: 209-18.
13. Schneider S, Manolopoulos K, Klein HH (2007) Das metabolische Syndrom. Versicherungsmedizin 59:115-119
14. Thöns M, Müller S, Klein HH (2009) Therapie bei diabetologischen Notfällen. InFo Diabetologie 3:2-5
15. Schütt M, Klein HH (2011) Neue Möglichkeiten der Differenzialtherapie des Typ-2- Diabetes. Internist 52:395-404
16. Landgraf R, Kellerer M, Fach E Gallwitz B, Hamann A, Joost HG, Klein HH, Mueller-Wieland, Nauck MA, Reuter H-M, Schreiber S, Siegel E, Matthaei S (2013) Praxisempfehlungen der DDG und DGIM für die Behandlung des Typ 2-Diabetes (aktualisiert) Diabetologie und Stoffwechsel S146-S151
17. Landgraf R, Kellerer M, Fach E Gallwitz B, Hamann A, Joost HG, Klein HH, Mueller-Wieland, Nauck MA, Reuter H-M, Schreiber S, Siegel E, Matthaei S(2014) Praxisempfehlungen der DDG und DGIM für die Behandlung des Typ 2-Diabetes (aktualisiert) Diabetologie und Stoffwechsel S138-S148
18. Pfeiffer AF, Klein HH (2014) The treatment of type 2 diabetes. Dtsch Arztebl Int 111: 69-81
19. Landgraf R, Kellerer M, Fach E Gallwitz B, Hamann A, Joost HG, Klein HH, Mueller-Wieland, Nauck MA, Reuter H-M, Schreiber S, Siegel E, Matthaei S (2015) Praxisempfehlungen der DDG und DGIM für die Behandlung des Typ 2-Diabetes (aktualisiert) Diabetologie und Stoffwechsel S140-S151
20. Köditz R, Klein HH (2016) Osteoporose-Prophylaxe: Mehr Kalzium beeinflusst Knochendichte und Frakturrisiko kaum. Dtsch Med Wochenschr 141:10
21. Dietrich JW, Landgrafe-Mende G, Wiora E, Chatzitomaris A, Klein HH, Midgley JEM and Hoermann R (2016) Calculated Parameters of Thyroid Homeostasis: Emerging Tools for Differential Diagnosis and Clinical Research. Front. Endocrinol. 7:57
22. Landgraf R, Kellerer M, Fach E Gallwitz B, Hamann A, Joost HG, Klein HH, Mueller-Wieland, Nauck MA, Reuter H-M, Schreiber S, Siegel E (2016) Therapie des Typ 2-Diabetes. Diabetologie und Stoffwechsel 11(S 02): S117-S129
23. Pfeiffer A. F. H., Gebauer S, Rubin D, Schulze M., Buchholz G., Klein H., Lilienfeld-Toal, Reinert G,, Simon M, Müssig K Skurk T, Hauner H, Tombek A, Müller M. J, Fischer S, Weickert M. O, Hoffmann D (2016) Ernährungsem-
    pfehlungen zur Behandlung des Diabetes mellitus – Empfehlungen zur Proteinzufuhr Diabetologie und Stoffwechsel 11:272-282
24. Landgraf, R, Kellerer M, Fach, EM, Gallwitz B, Hamann A, Joost H-G, Klein H, Müller-Wieland D, Nauck MA, Reuter H-M, Schreiber S, Siegel E (2017) Therapie des Typ 2-Diabetes. Diabetologie und Stoffwechsel 12 (S 02):S141-S156
25. Haak T, Gölz S, Fritsche A, Füchtenbusch M, Siegmund T, Schnellbächer E, Klein HH, Uebel T, Droßel D (2018) Therapie  des Typ 1-Diabetes – Kurzfassung der S3-Leitlinie (AWMF 057-13, 2. Auflage) Stand 30. Juni 2018. Diabetologie und Stoffwechsel 13 (S 02) S120-S130
26. Landgraf R, Kellerer M, Aberle J, Fach EM, Gallwitz B, Hamann A, Joost HG, Klein HH, Müller Wieland D, Nauck MA, Reuter HM, Schreiber S, Siegel E (2018) Therapie des Typ 2-Diabetes. Diabetologie und Stoffwechsel 13(S 02): S90-S96 S144-S165
27. Ehren M, Klein HH (2019) Insulintherapie-neue Insulinanaloga. Internist 60: 887-894. doi: 10.1007/s00108-019-0652-1
28. Landgraf R, Kellerer M, Aberle J, Fach EM, Gallwitz, B, Hamann A, Joost HG, Klein HH, Müller-Wieland D, Nauck MA, Reuter HM, Schreiber S, Siegel E (2019) Therapie des Typ 2-Diabetes. Diabetologe (2019) Diabetologie 14 (Suppl 2): S167–S187
29. Worms O. Klein HH (2019) Unerwünschte Wirkung der oralen Antidiabetika.

Intern Praxis, 61:346-351

30. Landgraf R, Aberle J, Birkenfeld AL; Gallwitz B, Kellerer M, Klein HH, Müller-Wieland D, Nauck MA, Reuter H-M, Siegel E (2020) Therapie des Typ 2-Diabetes. Diabetologie 15 (Supp 1) S65-S92
31. Haak T, Gölz S, Fritsche A, Füchtenbusch M, Siegmund T, Schnellbächer E, Klein HH, Uebel T, Droßel D (2020) Therapie des Typ-1-Diabetes. Kurzfassung der S3-Leitlinie (AWMF-Registernummer: 057-013; 2. Auflage) Diabetologie 2020; (Suppl 1): S40–S50

Buchartikel

1. Klein HH, Schneider S (2005-2006) Themengebiete Endokrinologie und Stoffwechsel. In: Brockhaus Enzyklopädie, 21. Aufl, Bibliographisches Institut & F. A. Brockhaus AG, Mannheim, ISBN: 978-3-577-90001-0
2. Klein HH (2009) Typ 2-Diabetes: Medizinische und sozioökonomische Aspekte einer durch Wohlstand ausgelösten Epidemie. In: Gesundheit: Geisteswissenschaftliche und Medizinische Aspekte, Hg: Geerlings W, Mügge A, LIT Verlag Dr W Hopf, Berlin, ISBN 978-3-643-10026-9
3. Ehren M, Burchard D, Müller-Wieland D, Klein HH (2011) Klinische Diabetologie: Operationen. In: Diabetologie in Klinik und Praxis 6. Auflage, Hg: Häring HU et al., Thieme, ISBN 978-3-13-512806-1, 326-330
4. Gallwitz B, Joost HG, Klein H, Matthaei S (2011) Insulinotrope orale Antidiabetika und inkretinbasierte Therapieformen. In: Diabetologie in Klinik und Praxis 6. Auflage, Hg: Häring HU et al., Thieme, ISBN 978-3-13-512806-1, 167-180
5. Klein HH (2013) Diabetes und andere endokrine Erkrankungen. In; Kursbuch Klinische Diabetologie, Hg. Nauck MA und Meier JJ, Kirchheim, ISBN 978-3874094351, 286-288
6. Klein HH (2013) Leitlinien der Deutschen Diabetes Gesellschaft. In: Diabetologie Kompakt, Hg. Schatz H und Pfeiffer AFH, Thieme, ISBN 978-3-642-41357-5, 34-36
7. Klein HH (2021) Orale Medikamente mit Einfluss auf die Insulinsensitivität. In Diabetologie in Klinik und Praxis, Hg Häring HU, Gallwitz B, Müller-Wieland D, Badenhoop K, Meier JJ, Usadel K-H, Mehnert H, Thieme, ISBN 978-313-242892-8, 203-206

Leitlinien

1. Pfeiffer A. F. H., Gebauer S, Rubin D, Schulze M., Buchholz G., Klein H., Lilienfeld-Toal, Reinert G,, Simon M, Müssig K Skurk T, Hauner H, Tombek A, Müller, M. J, Fischer S, Weickert M. O, Hoffmann D Ernährungsempfehlungen zur Behandlung des Diabetes mellitus – Empfehlungen zur Proteinzufuhr (2015) S3-Leitlinie AWMF 057-025
2. Haak T, Gölz S, Fritsche A, Füchtenbusch M, Siegmund T, Schnellbächer E, Klein HH, Spies C, Uebel T, Droßel D, Wiegand S Therapie des Typ 1-Diabetes S3-Leitlinie AWMF 057-13, 2. Auflage
3. Agostini H, Barkhausen J, Blödt S, Brockcamp C, Debus S, Dissemond J, Einhard N, Enax-Krumova E, Fründ A, Ghods M, Grundke S, Härder M, Hübner P, Joisten, C, Klein HH, Kopp I, Krirschner-Hermanns R, Krüger M, Kruse J, Landgraf R, Langhorst J, Lawall H, Layer P, Lehmann HC, Marx N, Mayer-Hasselmann A, Mertens N, Müller UA, Nothacker M, Petrak F, Pfersich T, Prien P, Rubin D, Rueb M, Rümenapf G, Schäfer C, Schmidt M, Schöbel C, Schöning D, Schorr S, Schüler S, Uebel T, Vader I, Westheide J, Zeyfang A Nationale VersorgungsLeitlinie (NVL) Typ-2-Diabetes – Teilpublikation, 2. Auflage, Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2 -Diabetes – Teilpublikation der Langfassung, 2. Auflage. Version 1. 2021 [cited: YYYY-MM-DD]. DOI: 10.6101/AZQ/000475. www.leitlinien.de/diabetes